Advertisement

Prostate Focused Ultrasound Therapy

  • Jean-Yves ChapelonEmail author
  • Olivier Rouvière
  • Sébastien Crouzet
  • Albert Gelet
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 880)

Abstract

The tremendous progress in engineering and computing power coupled with ultrasound transducer technology and imaging modalities over the past 20 years have encouraged a revival of clinical interest in ultrasound therapy, mainly in High-Intensity Focused Ultrasound (HIFU). So far, the most extensive results from HIFU obtained in urology involve transrectal prostate ablation, which appears to be an effective therapeutic alternative for patients with malignant prostate tumors. Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men. Several treatment options with different therapeutic approaches exist, including HIFU for localized PCa that has been in use for over 15 years. Since the early 2000s, two systems have been marketed for this application, and other devices are currently in clinical trials. HIFU treatment can be used either alone or in combination with (before- or after-) external beam radiotherapy (EBRT) (before or after HIFU) and can be repeated multiple times. HIFU treatment is performed under real-time monitoring with ultrasound or guided by MRI. Two indications are validated today: Primary care treatment and EBRT failure. The results of HIFU for primary care treatment are similar to standard conformal EBRT, even though no randomized comparative studies have been performed and no 10-year follow up data is yet available for HIFU. Salvage HIFU after EBRT failure is increasing with oncological outcomes, similar to those achieved with surgery but with the advantage of fewer adverse effects. HIFU is an evolving technology perfectly adapted for focal treatment. Thus, HIFU focal therapy is another pathway that must be explored when considering the accuracy and reliability for PCa mapping techniques. HIFU would be particularly suited for such a therapy since it is clear that HIFU outcomes and toxicity are relative to the volume of prostate treated.

Keywords

HIFU Prostate cancer 

References

  1. Ahmed HU, Cathcart P, McCartan N, Kirkham A, Allen C, Freeman A, Emberton M (2012a) Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer 118:4148–4155PubMedCrossRefGoogle Scholar
  2. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M (2012b) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 13:622–632PubMedCentralPubMedCrossRefGoogle Scholar
  3. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M (2009) High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 101:19–26PubMedCentralPubMedCrossRefGoogle Scholar
  4. AURO (2009) The association of italian urologists: guidelines, Prostate Cancer PCaGoogle Scholar
  5. Baco E, Gelet A, Crouzet S, Rud E, Rouvière O, Tonoli-Catez H, Berge V, Chapelon JY, Eggesbø HB (2014) Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer PCa: a prospective two-centre study. BJU Int 114:532–540PubMedCrossRefGoogle Scholar
  6. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757PubMedCentralPubMedCrossRefGoogle Scholar
  7. Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA, Debruyne FM, de la Rosette JJ (1999) High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 39:41–46PubMedCrossRefGoogle Scholar
  8. Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mège-Lechevallier F, Gelet A, Chapelon JY, Lyonnet D, Rouvière O (2008) MR detection of local prostate cancerPCa recurrence after transrectal high-intensity focused US treatment: preliminary results. J Radiol 89:571–577PubMedCrossRefGoogle Scholar
  9. Berge V, Baco E, Karlsen SJ (2010) A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol 44:223–227PubMedCrossRefGoogle Scholar
  10. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Adami HO, Johansson JE (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100:1144–1154PubMedCentralPubMedCrossRefGoogle Scholar
  11. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebillard X, Rewcastle JC, Robertson CN, Tueroff S, Ward JF, Gelet A (2009) Primary prostate HIFU without pretreatment hormone therapy: biochemical survival of 468 patients tracked with the @-registry. J Urol 181:227CrossRefGoogle Scholar
  12. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2008a) First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 53:1194–1201PubMedCrossRefGoogle Scholar
  13. Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B (2008b) Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 72:1329–1333; discussion 1333–13334PubMedCrossRefGoogle Scholar
  14. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24:585–590PubMedCrossRefGoogle Scholar
  15. Borghede G, Aldenborg F, Wurzinger E, Johansson KA, Hedelin H (1997) Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy. Br J Urol 80:247–255PubMedCrossRefGoogle Scholar
  16. Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mège-Lechevallier F, Colombel M, Rouvière O (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23:2019–2029PubMedCrossRefGoogle Scholar
  17. Challacombe BJ, Murphy DG, Zakri R, Cahill DJ (2009) High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. BJU Int 104:200–204PubMedCrossRefGoogle Scholar
  18. Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A (1992) In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 52:6353–6357PubMedGoogle Scholar
  19. Chaussy C, Thuroff S, Rebillard X, Gelet A (2005) Technology insight: high-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2:191–198PubMedCrossRefGoogle Scholar
  20. Chaussy C, Thuroff S (2001) Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 15:437–440; discussion 47–48PubMedCrossRefGoogle Scholar
  21. Cheikh AB, Girouin N, Colombel M, Maréchal JM, Gelet A, Bissery A, Rabilloud M, Lyonnet D, Rouvièrre O (2009) Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19:770–778PubMedCrossRefGoogle Scholar
  22. Chopra R, Tang K, Burtnyk M, Boyes A, Sugar L, Appu S, Klotz L, Bronskill M (2009) Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MRtemperature feedback. Phys Med Biol 54:2615–2633PubMedCrossRefGoogle Scholar
  23. Chopra R, Colquhoun A, Burtnyk M, N’djin WA, Kobelevskiy I, Boyes A, Siddiqui L, Foster H, Sugar L, Haider MA, Bronskill M, Klotz L (2012) MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology 265:303–313PubMedCrossRefGoogle Scholar
  24. Cornud F, Khoury G, Bouazza N, Beuvon F, Peyromaure M, Flam T, Zerbib M, Legmann P, Delongchamps NB (2014) Tumor target volume for focal therapy of prostate cancer: does multiparametric MRI allow for a reliable estimation? J Urol 191:1272–1279PubMedCrossRefGoogle Scholar
  25. Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, Martin X, Gelet A (2014) Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 65:907–914PubMedCrossRefGoogle Scholar
  26. Crouzet S, Murat FJ, Pasticier G, Cassier P, Chapelon JY, Gelet A (2010a) High intensity focused ultrasound (HIFU) for prostate cancer: current clinical status, outcomes and future perspectives. Int J Hyperthermia 26:796–803PubMedCrossRefGoogle Scholar
  27. Crouzet S, Murat FJ, Pommier P, Poissonnier L, Pasticier G, Rouviere O, Chapelon JY, Rabilloud M, Belot A, Mège-Lechevallier F, Tonoli-Catez H, Martin X, Gelet A (2012) Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. Radiother Oncol 105:198–202PubMedCrossRefGoogle Scholar
  28. Crouzet S, Murat FJ, Rouviere O, Poissonnier L, Martin X, Colombel M et al (2010b) Oncological outcomes of HIFU for localized prostate cancer in 880 consecutive patients. BJU Int 58:559–566Google Scholar
  29. Crouzet S, Poissonnier L, Murat FJ, Pasticier G, Rouviere O, Mege-Lechevallier F, Chapelon JY, Martin X, Gelet A (2011) Outcomes of HIFU for localised prostate cancer using the Ablatherm Integrate Imaging® device. Prog Urol 21:191–197PubMedCrossRefGoogle Scholar
  30. Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouvière O, Chapelon JY, Gelet A (2010c) Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58:559–566PubMedCrossRefGoogle Scholar
  31. Donati OF, Jung SI, Vargas HA, Gultekin DH, Zheng J, Moskowitz CS, Hricak H, Zelefsky MJ, Akin O (2013) Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268:440–450PubMedCrossRefGoogle Scholar
  32. Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martignoni G, Artibani W (2006) Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 98:1193–1198PubMedCrossRefGoogle Scholar
  33. Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M (2011) Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 185:1246–1254PubMedCrossRefGoogle Scholar
  34. Ganzer R, Fritsche HM, Brandtner A, Bründl J, Koch D, Wieland WF, Blana A (2013) Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 112:322–329PubMedCrossRefGoogle Scholar
  35. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A (2008) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 53:547–553PubMedCrossRefGoogle Scholar
  36. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y (1999) Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 161:156–162PubMedCrossRefGoogle Scholar
  37. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lasne Y, Lyonnet D, Dubernard JM (2000) Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 14:519–528PubMedCrossRefGoogle Scholar
  38. Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF, Cathignol D, Dubernard JM (1996) Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 29:174–183PubMedGoogle Scholar
  39. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Cathignol D, Blanc E (1993a) Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J Endourol 7:249–253PubMedCrossRefGoogle Scholar
  40. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, Bouvier R (1993b) High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol 23(Suppl 1):44–47PubMedGoogle Scholar
  41. Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Maréchal JM, Colombel M, Lyonnet D, Rouvière O (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17:1498–1509PubMedCrossRefGoogle Scholar
  42. Habchi H, Bratan F, Paye A, Pagnoux G, Sanzalone T, Mège-Lechevallier F, Crouzet S, Colombel M, Rabilloud M, Rouvière O (2014) Value of prostate multiparametric magnetic resonance imaging for predicting biopsy results in first or repeat biopsy. Clin Radiol 69:e120–128PubMedCrossRefGoogle Scholar
  43. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430PubMedCrossRefGoogle Scholar
  44. Hambrock T, Vos PC, Hulsbergen-van de Kaa CA, Barentsz JO, Huisman HJ (2013) Prostate cancer: computer-aided diagnosis with multiparametric 3-T MR imaging – effect on observer performance. Radiology 266:521–530PubMedCrossRefGoogle Scholar
  45. Heidenreich A, Richter S, Thuer D, Pfister D (2010) Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 57:437–443PubMedCrossRefGoogle Scholar
  46. Kennedy JE, Ter Haar GR, Cranston D (2003) High intensity focused ultrasound: surgery of the future? Br J Radiol 76:590–599PubMedCrossRefGoogle Scholar
  47. Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C (2008) MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 246:833–844PubMedCrossRefGoogle Scholar
  48. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRefGoogle Scholar
  49. Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, Sanghvi NT (2007) Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol 178:2366–2370; discussion 70–71PubMedCrossRefGoogle Scholar
  50. Lawrentschuk N, Finelli A, Van der Kwast TH, Ryan P, Bolton DM, Fleshner NE, Trachtenberg J, Klotz L, Robinette M, Woo H (2011) Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. J Urol 185:862–868PubMedCrossRefGoogle Scholar
  51. Le Nobin J, Orczyk C, Deng FM, Melamed J, Rusinek H, Taneja SS, Rosenkrantz AB (2014) Prostate tumor volumes: agreement between MRI and histology using novel co-registration software. BJU Int 114(6b):E105–12PubMedCrossRefGoogle Scholar
  52. Lee HM, Hong JH, Choi HY (2007) High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 9:439–443CrossRefGoogle Scholar
  53. Lemaitre L, Puech P, Poncelet E, Bouyé S, Leroy X, Biserte J, Villers A (2009) Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 19:470–480PubMedCrossRefGoogle Scholar
  54. Li LY, Lin Z, Yang M, Gao X, Xia TL, Ding T (2010) Comparison of penile size and erectile function after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer: a prospective pilot study. J Sex Med 7:3135–3142PubMedCrossRefGoogle Scholar
  55. Lynn JG, Putnam TJ (1944) Histology of cerebral lesions produced by focused ultrasound. Am J Pathol 20:637–649PubMedCentralPubMedGoogle Scholar
  56. Lynn JG, Zwemer RL, Chick AJ, Miller AE (1942) A new method for the generation and use of focused ultrasound in experimental biology. J Gen Physiol 26:179–193PubMedCentralPubMedCrossRefGoogle Scholar
  57. Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, Marberger M (1993) Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol 23(Suppl 1):39–43PubMedGoogle Scholar
  58. Maestroni U, Ziveri M, Azzolini N, Dinale F, Ziglioli F, Campaniello G, Frattini A, Ferretti S (2008) High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results. Acta Biomed 79:211–216PubMedGoogle Scholar
  59. Mearini L, D’Urso L, Collura D, Zucchi A, Costantini E, Formiconi A, Bini V, Muto G, Porena M (2009) Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 181:105–111; discussion 11-2PubMedCrossRefGoogle Scholar
  60. Misrai V, Roupret M, Chartier-Kastler E, Comperat E, Renard-Penna R, Haertig A, Bitker MO, Richard F, Conort P (2008) Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol 26:481–485PubMedCrossRefGoogle Scholar
  61. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55:640–647PubMedCrossRefGoogle Scholar
  62. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S (2008) Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38:192–199PubMedCrossRefGoogle Scholar
  63. Niaf E, Lartizien C, Bratan F, Roche L, Rabilloud M, Miège-Lechevallier F, Rouvière O (2014) Prostate focal peripheral zone lesions: characterization at multiparametric MR imaging – influence of a computer-aided diagnosis system. Radiology 271:761–769PubMedCrossRefGoogle Scholar
  64. Pasticier G, Riviere J, Wallerand H, Robert G, Bernhard JC, Ferriere JM, Ballanger P, Richaud P, Maire J, Chapet O, Gelet A (2010) Salvage Radiotherapy (SRT) for local recurrence of prostate adenocarcinoma after primary treatment with High Intensity Focused Ultrasound (HIFU): first series of 100 patients. ASCO Genitourinary Cancer Symposium San Francisco, California 2010;5–7Google Scholar
  65. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51:381–387PubMedCrossRefGoogle Scholar
  66. Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mège-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy – prospective multicenter study. Radiology 268:461–469PubMedCrossRefGoogle Scholar
  67. Rebillard X, Davin JL, Soulie M (2003) Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 13:1428–1456PubMedGoogle Scholar
  68. Ripert T, Bayoud Y, Messaoudi R, Menard J, Azemar MD, Duval F, Nguyen TD, Staerman F (2011) Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy. Can Urol Assoc J 1:1–5Google Scholar
  69. Riviere J, Bernhard JC, Robert G, Wallerand H, Deti E, Maurice-Tison S, Ardiet JM, Maire JP, Richaud P, Ferriere JM, Ballanger P, Gelet A, Pasticier G (2010) Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer. Eur Urol 58:567–573PubMedCrossRefGoogle Scholar
  70. Rosenkrantz AB, Kim S, Lim RP, Hindman N, Deng FM, Babb JS, Taneja SS (2013) Prostate cancer localization using multiparametric MR imaging: comparison of prostate imaging reporting and data system (PI-RADS) and likert scales. Radiology 269:482–492PubMedCrossRefGoogle Scholar
  71. Rouviere O, Gelet A, Crouzet S, Chapelon JY (2012a) Prostate focused ultrasound focal therapy – imaging for the future. Nat Rev Clin Oncol 9:721–727PubMedCrossRefGoogle Scholar
  72. Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mège-Lechevallier F, Rabilloud M, Chapelon JY, Lyonnet D (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20:48–55PubMedCrossRefGoogle Scholar
  73. Rouvière O, Glas L, Girouin N, Mège-Lechevallier F, Gelet A, Dantony E, Rabilloud M, Chapelon JY, Lyonnet D (2001a) Transrectal HIFU ablation of prostate cancer: assessment of tissue destruction with contrast-enhanced ultrasound. Radiology 259:583–591CrossRefGoogle Scholar
  74. Rouvière O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A (2001b) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40:265–274PubMedCrossRefGoogle Scholar
  75. Rouviere O, Mège-Lechevallier F, Chapelon JY, Gelet A, Bouvier R, Boutitite F, Lyonnet D (2006) Evaluation of color doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 50:490–497PubMedCrossRefGoogle Scholar
  76. Rouviere O, Papillard M, Girouin N, Boutier R, Rabilloud M, Riche B, Mège-Lechevallier F, Colombel M, Gelet A (2012b) Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? Eur Radiol 22:1149–1157PubMedCrossRefGoogle Scholar
  77. Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D (2007) Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur J Radiol 63:317–327PubMedCrossRefGoogle Scholar
  78. Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chalepon JY, Gelet A, Lyonnet D (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor – correlation with biopsy findings. Urology 63:922–927PubMedCrossRefGoogle Scholar
  79. Roy C, Foudi F, Charton J, Jung M, Lang H, Saussine C, Jacqmin D (2013) Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am J Roentgenol 200:W361–368PubMedCrossRefGoogle Scholar
  80. Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T (2010) Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol 17:715–719PubMedCrossRefGoogle Scholar
  81. Siddiqui K, Chopra R, Vedula S, Sugar L, Haider M, Boyes A, Musquera M, Bronskill M, Klotz L (2010) MRIguided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology 76:1506–1551PubMedCrossRefGoogle Scholar
  82. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC (2010) Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 81:376–381PubMedCrossRefGoogle Scholar
  83. Tavakkoli J, Sanghvi NT (2011) Ultrasound-guided HIFU and thermal ablation. In: Frenkel V (ed) Therapeutic ultrasound: mechanisms to applications, Chapter 6. Nova Science Publishers, Hauppauge, pp 137–161Google Scholar
  84. Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, Desgrandchamps F, De La Rosette JJ, Gelet A (2003) High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17:673–677PubMedCrossRefGoogle Scholar
  85. Thüroff S, Chaussy C (2013) Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol 190:702–710PubMedCrossRefGoogle Scholar
  86. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC, Albert PS, Merino MJ, Choyke PL (2010) Prostate cancer: value of multiparametric MR imaging at 3 T for detection – histopathologic correlation. Radiology 255:89–99PubMedCentralPubMedCrossRefGoogle Scholar
  87. Uchida T, Illing RO, Cathcart PJ, Emberton M (2006a) To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 98:537–539PubMedCrossRefGoogle Scholar
  88. Uchida T, Nakano M, Shoji S, Omaat T, Harano H, Nagata Y et al (2009) Ten Year Biochemical disease free survival after high intensity focused ultrasound (HIFU) for localised prostate cancer: comparison with three different generation devices. Conference: 104th Annual Meeting of the American-Urological-Association Location: Chicago, IL Date: APR 25–30, 2009. J Urol 181:228–228CrossRefGoogle Scholar
  89. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A (2006b) Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 97:56–61PubMedCrossRefGoogle Scholar
  90. Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, Satoh T (2006c) Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 13:228–233PubMedCrossRefGoogle Scholar
  91. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Usui Y, Nagata Y (2010) High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int 107:378–382PubMedCrossRefGoogle Scholar
  92. Vache T, Bratan F, Mege-Lechevallier F, Roche S, Rabilloud M, Rouviere O (2014) Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology 272:446–455PubMedCrossRefGoogle Scholar
  93. Van Velthoven R, Aoun F, Limani K, Narahari K, Lemort M, Peltier A (2014) Primary zonal high intensity focused ultrasound for prostate cancer: results of a Prospective Phase IIa Feasibility Study. Prostate Cancer 2014:756189PubMedCentralPubMedGoogle Scholar
  94. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176:2432–2437PubMedCrossRefGoogle Scholar
  95. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M (2008) The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 102:786–792PubMedCrossRefGoogle Scholar
  96. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876–881PubMedCrossRefGoogle Scholar
  97. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179:1368–1373; discussion 73PubMedCentralPubMedCrossRefGoogle Scholar
  98. Zini C, Hipp E, Thomas S, Napoli A, Catalano C, Oto A (2012) Ultrasound- and MR-guided focused ultrasound surgery for prostate cancer. World J Radiol 4:247–252PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Jean-Yves Chapelon
    • 1
    • 2
    Email author
  • Olivier Rouvière
    • 1
    • 2
    • 3
  • Sébastien Crouzet
    • 1
    • 2
    • 4
  • Albert Gelet
    • 1
    • 2
    • 4
  1. 1.INSERM, U1032LyonFrance
  2. 2.Laboratory of Therapeutic Applications of UltrasoundUniversité Lyon 1LyonFrance
  3. 3.Department of RadiologyHospices Civils de Lyon, Edouard Herriot HospitalLyonFrance
  4. 4.Department of UrologyHospices Civils de Lyon, Edouard Herriot HospitalLyonFrance

Personalised recommendations